MDAI

MDAI
Clinical data
Routes of; administration	Oral
ATC code	none;
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act; Illegal in China;
Identifiers
	IUPAC name 6,7-Dihydro-5H-cyclopenta[f] [1,3]benzodioxol-6-amine;
CAS Number	132741-81-2;
PubChem CID	125558;
ChemSpider	111694 ;
UNII	0DMJ6G3XBF;
CompTox Dashboard (EPA)	DTXSID60157741 ;
Chemical and physical data
Formula	C10H11NO2
Molar mass	177.203 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C(CC2=CC3=C(C=C21)OCO3)N;
	InChI InChI=1S/C10H11NO2/c11-8-1-6-3-9-10(13-5-12-9)4-7(6)2-8/h3-4,8H,1-2,5,11H2 ; Key:FQDRMHHCWZAXJM-UHFFFAOYSA-N ;

MDAI (5,6-methylenedioxy-2-aminoindane) is a drug developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic and highly selective serotonin releasing agent (SSRA) in vitro and produces entactogen effects in humans.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.